Topics
October 2015 | Special Focus: Uveitis
Promising Pipeline for Treatment of Noninfectious Posterior Uveitis
Agents and delivery mechanisms in development may offer physicians assistance in treating this heterogeneous disorder.
Steven Yeh, MD
October 16, 2026
Alvotech and Advanz Pharma Submit European Application for First Proposed Eylea 8 mg Biosimilar
FDA Approves Genentech's Enspryng as First At-Home Subcutaneous Treatment for Thyroid Eye Disease
October 15, 2026
Study Finds Rising Demand for Emergency Ophthalmology Consultations Across US Academic Centers
Eclipse Life Sciences Reports Positive Phase 2 Results for EC-104 in DME
October 2026 Insert
Editorially Independent Content, Supported With Advertising From Asetllas
Editorially independent supported by Abbvie and Regenxbio
Free Print Subscription
Email Newsletter
Conference Calendar
